Sarpogrelate is a drug which acts as an antagonist at the serotonin 5-HT2A 5-HT2B, and 5-HT2C receptors. However, its affinities for the human 5-HT2C and 5-HT2B receptors are about one and two orders of magnitude lower than for the human 5-HT2A receptor. Technically, sarpogrelate is supplied as a pharmaceutically acceptable salt and functions principally by blocking 5-HT2A-mediated platelet activation and serotonin-induced vasoconstriction, which reduces platelet aggregation and improves peripheral and microvascular blood flow. Pharmacodynamic effects include inhibition of serotonin-triggered shape change and granule release in platelets and antagonism of vascular smooth muscle 5-HT2A receptors. From a pharmacokinetic perspective, oral formulations show systemic exposure with first pass metabolism primarily via hepatic oxidative pathways; metabolites include hydroxylated and dealkylated species that are characterized in metabolic profiling. Standard preclinical in vitro assays use radioligand and cellular functional assays to quantify receptor binding and antagonism, and standard safety pharmacology screens assess cardiac ion channel interactions and 5-HT2B liability to rule out agonist-mediated valvulopathy risk.
![2-[2-(3-Methoxyphenyl)ethenyl]phenol](https://veeprho.com/wp-content/uploads/2025/04/VE0023603-2-2-3-Methoxyphenyl-ethenyl-phenol.png "2-[2-(3-Methoxyphenyl)ethenyl]phenol")
Parent: Sarpogrelate
Typical quality control for sarpogrelate active pharmaceutical ingredient uses validated HPLC and LC-MS methods for assay and related-substance profiling and gas chromatography or headspace GC for residual solvents; limits are set to meet ICH guidelines. Representative specification ranges applied in development and regulatory filings are total impurities not greater than 1.0% w/w, individual unspecified impurities not greater than 0.10% w/w, and identified or specified related compounds commonly limited to 0.2 to 0.5% w/w depending on impurity safety assessment. Control of oxidation and hydrolysis degradants, common oxidative metabolites such as mono-hydroxylated species and dealkylated derivatives, is achieved by process controls and stability-indicating methods. Where chirality is relevant, enantiomeric purity is typically controlled by chiral HPLC to at least 98% ee. Residual solvent and elemental impurity limits follow ICH Q3C and Q3D thresholds and are evaluated case by case.
Sarpogrelate is used to inhibit serotonin-mediated platelet aggregation and to reduce vasoconstriction mediated by 5-HT2A receptors, with clinical applications focused on improving peripheral circulation and reducing thrombotic risk related to serotonin-driven platelet activation. Its pharmacological profile makes it useful in disorders where platelet serotonin release and vascular 5-HT2A signaling contribute to pathology.
Clopidogrel is an ADP receptor P2Y12 inhibitor that prevents platelet aggregation by blocking ADP-induced activation of the GPIIb/IIIa pathway, while sarpogrelate is a serotonin receptor antagonist that specifically blocks 5-HT2A-mediated platelet activation and serotonin-induced vasoconstriction. Mechanistically they target distinct platelet activation pathways, so their pharmacology, indications, onset of action, metabolism, and interaction profiles differ.
